Patents by Inventor Derk Jon Bergsma

Derk Jon Bergsma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6187544
    Abstract: The present invention provides a method for high throughput cloning of full length cDNA sequences using a pooling strategy. This method uses a plurality of clone arrays prepared from cDNA libraries which have been preferably enriched for 5 ′ mRNA sequences and size fractionated into several discrete ranges (sub-libraries). These arrays are used to rapidly identify the full length cDNA sequence for a DNA segment of interest.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: February 13, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Derk Jon Bergsma, Jeffrey L Mooney
  • Patent number: 6166182
    Abstract: Human neurotensin type 2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing human neurotensin type 2 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: December 26, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Derk Jon Bergsma, Usman Shabon
  • Patent number: 6033872
    Abstract: Human 11cb splice variant polypeptides and DNA (RNA) encoding such an 11cb splice variant and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such an 11cb splice variant for the treatment of infections, such as bacterial, fungal, protozoan and viral infections, particularly infection caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; both acute and congestive heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; allergies; benign prostatic hypertrophy and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia or severe mental retardation; dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others.
    Type: Grant
    Filed: December 3, 1997
    Date of Patent: March 7, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Derk Jon Bergsma, Catherine Elizabeth Ellis
  • Patent number: 6010877
    Abstract: HE8CS41 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HE8CS41 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: January 10, 1997
    Date of Patent: January 4, 2000
    Assignee: SmithKline Beecham Corporation
    Inventors: Ganesh M Sathe, Stephanie Van Horn, Derk Jon Bergsma, Joyce Yue Mao
  • Patent number: 6008050
    Abstract: Human neurotensin type 2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing human neurotensin type 2 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: December 28, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Derk Jon Bergsma, Usman Shabon
  • Patent number: 6008012
    Abstract: This invention relates to a novel human somatostatin-like receptor, isolated nucleic acids encoding same, recombinant host cell transformed with an somatostatin-like receptor encoding DNA and to uses of the expressed receptor and nucleic acid sequences in drug screening and development as well as in therapeutic and diagnostic applications.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: December 28, 1999
    Assignee: Smithkline Beecham Corporation,
    Inventors: Derk Jon Bergsma, Catherine Elizabeth Ellis
  • Patent number: 5942405
    Abstract: Human C3a Receptor polypeptides and DNA (RNA) encoding such C3a Receptor and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such C3a Receptor for the treatment of inflammatory and auto-immune disorders, among others. Antagonists against such C3a Receptor and their use as a therapeutic to treat inflammatory and auto-immune disorders, among others, are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the C3a Receptor and for detecting altered levels of the polypeptide in a host.
    Type: Grant
    Filed: June 16, 1997
    Date of Patent: August 24, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert S Ames, Derk Jon Bergsma, James J Foley, Chandrika Saidapet-Kumar, Henry M Sarau
  • Patent number: 5880105
    Abstract: This invention relates to human galactokinase and the identification of galactokinase mutations, a missense and nonsense, as well as isolated nucleic acids encoding same, recombinant host cell transformed with DNA encoding such proteins and to uses of the expressed proteins and nucleic acid sequences in therapeutic and diagnostic applications.
    Type: Grant
    Filed: December 24, 1997
    Date of Patent: March 9, 1999
    Assignees: SmithKline Beecham Corporation, The Trustees of the University of Pennsylvania
    Inventors: Derk Jon Bergsma, Dwight Edward Stambolian, Steven M. Ruben, Craig A. Rosen
  • Patent number: 5830649
    Abstract: This invention relates to human galactokinase and the identification of galactokinase mutations, a missense and nonsense, as well as isolated nucleic acids encoding same, recombinant host cell transformed with DNA encoding such proteins and to uses of the expressed proteins and nucleic acid sequences in therapeutic and diagnostic applications.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: November 3, 1998
    Assignee: SmithKline Beecham Corporation
    Inventors: Derk Jon Bergsma, Dwight Edward Stambolian
  • Patent number: 5789223
    Abstract: This invention relates to human galactokinase and the identification of galactokinase mutations, a missense and nonsense, as well as isolated nucleic acids encoding same, recombinant host cell transformed with DNA encoding such proteins and to uses of the expressed proteins and nucleic acid sequences in therapeutic and diagnostic applications.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: August 4, 1998
    Assignees: SmithKline Beecham Corporation, The Trustees of the University of Pennsylvania
    Inventors: Derk Jon Bergsma, Dwight Edward Stambolian, Steven M. Ruben, Craig A. Rosen